Scientific and medical literature is an important source of information on suspected adverse reaction case reports. Currently, for active substances included in more than one medicinal product for human use, literature cases are reported in adverse reaction case reports in a duplicative way. In order to enhance the efficiency of reporting, the Agency should monitor a defined list of literature for a defined list of active substances used in medicinal products for which there are several marketing authorisations.
Recital 19, Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…
In forcesince 15 Dec 2010